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Abstract
Background: Goals of treating major depressive disorder (MDD) include achieving remission and avoiding relapse.
It is possible that patients may have a broader view of remission than what is captured via clinician-rated scales.
This patient perspective may, in turn, have an impact on treatment outcomes.
Methods: The association between a broader conceptualization of remission, based on the Remission from
Depression Questionnaire (RDQ) score at baseline, and being in symptomatic remission after 6 months was
evaluated in subjects (N = 613) with MDD in symptomatic remission at baseline (17-item Hamilton Rating Scale for
Depression [HAMD-17] ≤7). Specific aspects of depression were assessed from physician and patient perspectives as
secondary endpoints. A backwards selection strategy was used to statistically model remission status and determine
association of factors with potential to influence remission.
Results: At month 6, after adjustment for baseline HAMD-17 score, there was no association between baseline RDQ
score and symptomatic remission status (HAMD-17), relapse, composite remission status, healthcare resource
utilization, or quality of life. There was no association between functional impairment scores at baseline (Sheehan
Disability Scale and Social and Occupational Functioning Assessment Scale) and symptomatic remission status
(HAMD-17) at month 6.
Conclusions: This study indicates that RDQ-constructs are independent from symptomatic remission. Symptom
severity at study entry appeared to be the only significant predictor of eventual relapse during the 6-month follow-up
period. However, our results also suggest that the current definition of remission that is based on symptom reduction
should be further elaborated and that alternative or additional definitions should be considered in determining
remission.
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Background
Current standards for treatment of major depressive dis-
order (MDD) recommend that achieving remission
should be considered the principal goal [1]. However, in
the absence of biological markers, remission from
depression has proven to be an elusive construct to
capture and apply. In antidepressant efficacy trials,
remission is typically defined in terms of the absence of
symptoms on measures such as the Hamilton Rating
Scale for Depression (HAMD) [2] or Montgomery–
Åsberg Depression Rating Scale (MADRS) [3]. However,
exclusively symptom-based definitions may be funda-
mentally limited in scope [1]. While normalization of
function is considered important in the definition of
remission, it is not identified by the scales. Moreover,
depressed patients have a more inclusive perception
about what remission from a depressive episode means.
The presence of features of positive mental health, a
return to one’s normal self, and a return to usual level of
functioning were more important to patients than the
disappearance of depressive symptoms alone when they
considered their remission status [4]. In fact, discord-
ance can occur between clinicians’ and patients’ percep-
tions of remission [5]. In a previous study, Zimmerman
and colleagues found that approximately half of patients
scoring in the remission range on the HAMD did not
consider themselves to be in remission [6]. In support of
these observations, the use of patient-reported outcome
scales in clinical trials conducted by the pharmaceutical
industry has become more widespread [7].
Acknowledging that symptom-based measures do not
accommodate these additional factors [3, 4], researchers
have advocated a broader conceptualization of remission
that includes factors beyond depressive symptoms [8, 9].
The recently developed Remission from Depression
Questionnaire (RDQ) assesses remission in a broader
and multidimensional way. The RDQ is patient-
completed and addresses other symptoms often present
in depressed patients, such as anxiety and irritability,
features of positive mental health, coping ability, func-
tioning, life satisfaction, and a general sense of well-
being [10].
One of the principal goals of defining remission is to
predict future morbidity. The basis for the emphasis on
“treating to remission” is the consistent finding that
treatment responders who meet the threshold for symp-
tomatic remission are significantly less likely to relapse
than those who do not [4]. The patient perspective on
remission is broad and multidimensional, while the
current definition of remission based on the 17-item
Hamilton Rating Scale for Depression (HAMD-17) is
focused on clinical symptoms of depression only. The
implication of this different conceptualization of
remission on prognosis has not been studied previously.
We describe here the results of a multicenter, observa-
tional study in depressed patients in symptomatic remis-
sion who were treated in routine clinical practice. The
primary objective of the study was to determine whether
RDQ score at the end of an acute treatment phase
(study baseline) was associated with symptomatic remis-
sion, defined using the HAMD-17 total score at month
6. Our secondary objectives included assessment of the
association of remission as measured by the RDQ with
an alternative definition of relapse, and also with a com-
posite remission status measured by a combination of
clinical, functional, and quality of life criteria, healthcare
resource use, and quality of life. Additionally, we
assessed the association of symptomatic remission at
month 6 (by HAMD-17) with patient-rated or clinician-
rated baseline functioning status evaluated by Sheehan
Disability Scale (SDS) or Social and Occupational
Functioning Assessment Scale (SOFAS), respectively.
Our hypothesis was that in patients with MDD who
are in symptomatic remission based on the HAMD
(HAMD-17 ≤ 7) after the acute treatment of a depressive
episode, a broad perspective of remission based on the
RDQ at completion of an acute treatment phase, is asso-
ciated with being in symptomatic remission at the end
of the 6-month follow-up period.
Methods
Study design and participants
This prospective, multicenter, observational study was
conducted in 613 subjects at 39 centers in Spain from
June 2012 to July 2013 (first and last subject visit). The
study was conducted in accordance with the ethical
principles that have their origin in the Declaration of
Helsinki and are consistent with Good Clinical Practice
guidelines. The protocol was submitted and approved by
appropriate ethical review boards. All subjects provided
written informed consent before enrollment in the
study.
Treatment for the current major depressive episode
was solely at the discretion of the physician and was
prescribed in the usual standard of care. Participation in
the study did not influence payment or reimbursement
for any treatment received by subjects during the study.
The study included visits at baseline and month 6
(±2 weeks). Additionally, the assessment of relapse at
month 6 covered the entire 6-month period from base-
line. Baseline patient characteristics including history of
MDD (any prior episode of MDD before the episode
referred to for inclusion in the study), MDD treatment
history, chronic somatic co-morbidities, concomitant
therapy, and medications/MDD treatment were summa-
rized for the full analysis set (FAS), by month 6 depres-
sion status (by HAMD-17 remission status), and overall.
Validated survey instruments were administered at each
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visit to assess clinical and health outcomes. Data, includ-
ing electronic patient-reported outcomes, were collected
electronically.
Outpatients ≥18 years of age with a diagnosis of MDD
(based on the Spanish validated version 6.0 Mini-
International Neuropsychiatric Interview (MINI) inter-
view [11]), who previously went through the acute treat-
ment phase (12 ± 2 weeks prior to baseline visit) of the
current depressive episode and were in symptomatic
remission, were recruited from private psychiatric
medical clinics. This window (12 ± 2 weeks) was used in
previous trials and was intended to capture patients in
remission after completion of a recent acute treatment
phase. Symptomatic remission was defined as a score of
≤7 on the HAMD-17 and the absence of a Diagnostic
and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) diagnosis of depression at baseline as assessed
by the MINI.
Outcome measures (definitions of remission, functioning,
and quality of life)
The primary objective of the study was to assess the
relationship between symptomatic remission evaluated
by the HAM-D17 at month 6 and baseline RDQ total
score.
Remission from Depression Questionnaire (RDQ)
The RDQ captures a broad array of domains including
symptoms of depression, non-depressive symptoms (e.g.,
anxiety and irritability), features of positive mental
health, coping ability, functioning, life satisfaction, and a
general sense of well-being that patients consider
important in determining their remission status. The
RDQ is a reliable and valid measure [12] with 41 items
and seven subscales. Items are reported on a 3-point
rating scale: 0 = not at all or rarely true; 1 = sometimes
true; and 2 = often or almost always true. Patients who
have RDQ total score ≤27 are considered in remission,
and higher item values reflect greater pathology. In this
study, the RDQ score is considered to represent the
patient’s perception of his or her own remission status
and reflects multidimensional factors often present in
depressed patients.
17-item Hamilton rating scale for depression (HAMD-17)
The HAMD-17 assesses the range of symptoms most
frequently observed in patients with MDD [2]. Remission
is defined in terms of the absence of symptoms, with
‘asymptomatic’ operationalized as a score of ≤7. In this
study, the HAMD-17 was used to assess symptomatic
remission at baseline and study end (month 6 [sustained
remission]).
The Mini-International Neuropsychiatric Interview (MINI)
The MINI is a psychiatric structured interview widely
used to establish psychiatric diagnosis according to the
DSM-IV. It is divided into modules corresponding to
different diagnostic categories. The MINI depression
module was used to establish the presence or absence of
a diagnosis of depression and to indicate relapse (re-
ported as relapse [yes/no]) at month 6 ± 2 weeks.
Quick Inventory of Depressive Symptomatology-Self Report
(QIDS-SR)
The Quick Inventory of Depressive Symptomatology–
Self Report (QIDS-SR) is a reliable and valid measure of
the DSM-IV symptom criteria of MDD [13]. In this
study, a score of ≤5 indicated remission (reported as
yes/no).
Social and Occupational Functioning Assessment Scale
(SOFAS)
The SOFAS indicates the level of social and occupational
functioning across a continuum, ranging from a state of
optimum functioning to a state of worst functional im-
pairment, without taking symptoms into account [14]. In
this study, results were reported as good/bad functioning
based on a score of ≥80 indicating good functioning [15].
Sheehan Disability Scale (SDS)
The SDS [16] is a patient-rated scale that assesses dis-
ability by evaluating impairment in work/school, social
life/leisure activities, and family life/home responsibil-
ities. In this study, results were reported in terms of
functional impairment with a total score ≥6 indicating
overall functional impairment reported as overall/no
overall functional impairment [17].
EuroQol (EQ-5D)
The EuroQol (EQ-5D), a widely used generic, health-
related (disease non-specific) quality of life instrument
[18], provides a utility score related to health status and
impact on usual life activities. In this study, index scores
using the Spanish value sets were reported [19]. Patients
with an index scores of >70.71 were considered in
remission (nonremission ≤70.71) [20].
Alternative definitions of remission
Association of baseline RDQ remission status with alter-
native definitions of remission/relapse was evaluated.
Depressive status evaluated by the MINI at month 6 was
used as an indication of relapse. Alternatively, 2 combi-
nations of outcome measures, the QIDS-SR, SDS, and
EQ-5D, and the HAMD-17 and SOFAS, provided a basis
for composite remission status. The composite scores
assessed a wide range of attributes. Briefly, the QIDS-SR,
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SDS, and EQ-5D measure depressive symptoms, disabil-
ity, and health-related quality of life, respectively.
Composite remission status (i.e., yes or no) was deter-
mined based on cutoffs for QIDS-SR, SDS, EQ-5D,
HAMD-17, and SOFAS. Patients who met the cutoff
criterion on each scale were considered as meeting the
criteria for composite remission. Patients who did not
meet the cutoff or missed information on any of the 3
scales (QIDS-SR, SDS, and EQ-5D) were considered as
not meeting the composite remission criterion.
Functioning
The association of symptomatic remission at month 6
(according to HAMD-17) with baseline functioning
status was assessed as patient-rated by the SDS or
clinician-rated by the SOFAS.
Resource utilization
The number and percentage of subjects using healthcare
resources, stratified by RDQ baseline status, were
analyzed in a descriptive manner. Moreover, the rela-
tionship between resource utilization and remission
status was explored by means of logistic regression ana-
lyses with resource utilization outcomes dichotomized
(Number of Visits >0 or not >0) for analysis.
Healthcare resource utilization, at baseline (utilization
in previous 30 days) and month 6 (all utilization in the
6 months between baseline and month 6), was based on
the following questions:
1. Has the subject used any additional healthcare
resources?
2. How many emergency room or equivalent facility
visits for psychiatric illness have occurred?
3. How many emergency room or equivalent facility
visits for nonpsychiatric illness have occurred?
4. How many outpatient visits to other physicians (not
psychiatrists) have occurred?
5. How many psychiatric visits have occurred?
6. How many hospitalizations for any reason have
occurred?
7. Is the subject currently on sick leave due to
depression?
Safety analyses
No safety information was collected for this study.




The FAS included all subjects who provided consent to
release information and fulfilled study entry criteria.
Determination of sample size
It was determined that a sample size of 499 observations
would achieve 80 % power at a 0.05 significance level to
detect a change in the probability of relapse from the
value of 0.15 at the mean of RDQ to 0.209 when RDQ
score is increased to 1 standard deviation (SD) above the
mean (calculation based on [21]). This change corre-
sponds to an odds ratio of 1.5. An adjustment was made
since a multiple regression of the independent variable
of interest on the other independent variables in the
logistic regression obtained an r2 of 0.25. Considering
that withdrawals were expected during the study




Total scores and subscale scores were summarized (as
applicable) for each clinical scale and questionnaire.
Summary statistics by time and remission status as well
as change from baseline were presented for those
questionnaires for which total scores could be derived.
Binary outcomes (e.g., remission status) and continu-
ous outcomes (e.g., change from baseline in RDQ) were
modeled with respect to other factors such as baseline
RDQ total score by logistic regression and linear regres-
sion, respectively. The initial models included baseline
severity of depression (as determined by HAMD-17),
age, gender, employment status, number of years since
diagnosis, family history of depression, history of MDD,
duration of treatment for current episode, and somatic co-
morbidities. The variable selection process began with re-
moving the largest nonsignificant p-values (i.e., p > 0.05)
one at a time while always retaining all other variables.
The significance of the reduced model was tested using
the likelihood ratio test and if significant, the previously
removed variable was returned to derive the final model.
The Hosmer-Lemeshow test was used to check for good-
ness of fit of the final logistic regression models while the
final linear regression model was tested against the null
model using the F-test.
To assess the association of function based on baseline
scores of the SOFAS and SDS and symptomatic remis-
sion at month 6 (as determined by HAMD-17), a new
model was developed that included SOFAS/SDS status
at baseline (dichotomized to good functioning/bad func-
tioning) as an independent variable. The same variable
selection process was applied as for the other outcomes,
however the variables severity of depression, sex, and
age were forced into the model.
Health outcomes
Subject quality of life at baseline and 6 months (as evalu-
ated by EQ-5D) and the association with the RDQ score
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at baseline was analyzed by means of an Analysis of
Covariance (ANCOVA) model. The model included the
change in the score as the dependent variable, the RDQ
status (i.e., remission, nonremission) at baseline, the
baseline value of the respective score as a covariate, as
well as baseline severity of the depression (as evaluated
by HAMD-17), sex, age, and other relevant baseline
variables. The same variable selection process was
applied as for the other outcomes.
Healthcare resource utilization variables were analyzed
in a descriptive manner, stratified by binary RDQ base-
line status. Moreover, the relationship between resource
utilization and the subject’s RDQ remission status at
baseline was explored by means of logistic regression
analyses. The effect of RDQ score on month-6 outcome
was assessed using the same modeling approach.
All analyses were performed using SAS 9.1.3 (or later)
for Windows, SAS Institute Inc., Cary, NC, USA. No
adjustment for multiple comparisons was made.
Results
The FAS included all 613 subjects enrolled in the study.
At the month-6 visit, 38 subjects had discontinued. Rea-
sons for discontinuation after baseline (n = 35) included
lost to follow-up (n = 20), site unresponsive (n = 12),
physician decision (n = 1), and subject decision (n = 2).
The mean (± SD) age of subjects in the study was 46.6
(13.5) years and the majority were female (68.8 %). Most
subjects had received university (38.5 %) or secondary
education (35.6 %), were able to work (76.2 %), and were
living with a family member (89.1 %). Approximately
half of the subjects (49.9 %) had a family history of
depression. This was not the first episode of MDD for
56.0 % (n = 343) of subjects. Further, 46.1 % of subjects
had received prior treatment. The most frequent
antidepressant drug treatment was selective serotonin
reuptake inhibitors (SSRI) (60.9 %). The mean treatment
period for prior episodes of MDD was 31.4 ±
40.4 months. There were no apparent differences in
demographic characteristics between subjects in remis-
sion at baseline and subjects not in remission (HAMD-
17) at month 6 (Table 1). The percentage of patients
who were in remission at baseline according to the
dichotomous definition was 75.2 %. The majority of
subjects (98.1 %) who were in remission according to
RDQ status at month 6 were also in remission by
according to HAMD-17.
For the current MDD episode, 96.1 % of subjects had re-
ceived prior treatment, 77.3 % were treated at baseline and
61.5 % were treated at month 6, respectively. Treatment
patterns were similar across visits, with antidepressants
being the most frequently administered: SSRIs (51.4 % at
baseline), serotonin norepinephrine reuptake inhibitors
(SNRIs) (34.3 % at baseline) and tricyclic antidepressants
(3.2 % at baseline) (Table 2).
Association of baseline RDQ with remission by HAMD-17
at month 6
The multivariate logistic regression model to evaluate
the association of RDQ status at baseline (as a continu-
ous or dichotomous variable) with sustained remission
showed that an increase in baseline HAMD-17 score of
1 unit significantly decreased the odds of the patient be-
ing in remission by 18 %, ([odds ratio [OR] 0.82, 95 %
confidence interval [CI] 0.70 to 0.96, p = 0.017) for the
model with RDQ status as a continuous variable (Fig. 1)
and by 19 %, (OR 0.81, 95 % CI 0.70 to 0.95, p = 0.009])
for the model with RDQ status as a dichotomous variable
(Table 3). The final selected model only included employ-
ment status, HAMD-17, and RDQ. Increasing RDQ by 1
unit did not change the odds of the patient being in sus-
tained remission (OR 1.0, 95 % CI 0.98 to 1.02, p = 0.925).
Remission for dichotomous RDQ at baseline decreased
the odds of the patient being in sustained remission by
11 % (OR 0.89, 95 % CI 0.59 to 1.33), although the
decrease was not significant (p = 0.568).
After adjustment of HAMD-17 score at baseline (the
scale used to measure baseline remission), there was no
association between baseline RDQ score as a continuous
or dichotomous variable and remission status (according
to HAMD-17) at month 6.
Alternative definitions of remission
Association of baseline RDQ score with MINI
The association of RDQ score at baseline with relapse at
month 6 measured by MINI, modeled by logistic regres-
sion, showed an increase of 1 unit in baseline RDQ was
associated with a nonsignificant decrease in the odds of
relapse by 2 % (OR 0.98, 95 % CI 0.96 to 1.00, p = 0.071).
In contrast, an increase in 1 unit in HAMD-17 at
baseline corresponded to a significant increase of 21 %
in the odds of relapse at 6 months (OR 1.21, 95 % CI
1.05 to 1.39, p = 0.007). Sex, age, and employment were
significant factors (p < 0.05).
Association of baseline RDQ with composite remission
status
Logistic regression models showed no association of
RDQ at baseline with composite remission status (i.e.,
yes/no) at month 6 measured by QIDS-SR, SDS, and
EQ-5D or by HAMD-17 and SOFAS. An increase in
RDQ score of 1 unit at baseline was associated with a
nonsignificant decrease of 1 % in the odds of being in
sustained remission for both composite scores (QIDS-
SR, SDS, and EQ-5D = OR 0.99, 95 % CI 0.96 to 1.02,
p = 0.553; HAMD-17 and SOFAS = OR 0.99, 95 % CI
0.97 to 1.01, p = 0.374).
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Patient’s functioning
Association of baseline functioning (SDS, SOFAS) with
remission per HAMD-17 at month 6
There was no association between remission scores
(HAMD-17 ≤ 7) at 6 months and both functional disabil-
ity scores (SDS) and good functioning scores (SOFAS) at
baseline. No overall functional disability at baseline cor-
responded to a 9 % nonsignificant increase in the odds
of being in remission at 6 months compared to overall
functional disability at baseline (OR 1.09, 95 % CI 0.57
to 2.09, p = 0.789).
Similarly, good functioning at baseline was associated
with a 3 % nonsignificant increase in the odds of being
in remission at 6 months compared to bad functioning
at baseline (OR 1.03, 95 % CI 0.55 to 1.95, p = 0.917).
Healthcare resource utilization and quality of life
Healthcare resource utilization was analyzed in a de-
scriptive manner stratified by binary RDQ status (i.e., re-
mission, nonremission) (Table 4). Use of additional
healthcare resources was similar at baseline for subjects
in remission (22.1 %) and subjects not in remission
(27.7 %). At month 6, healthcare resource utilization in-
creased to 35.2 % for subjects in sustained remission and
38.3 % for subjects not in sustained remission. Analysis
by ANCOVA showed that change from baseline EQ-5D
score was 0.023 points less for subjects in remission by
RDQ than for subjects not in remission (coefficient;
Table 1 Baseline characteristics for full analysis set and by
remission status at month 6
FAS Based on HAMD-17 at Month 6
N = 613 N = 575
Remission No Remission
n = 521 n = 54
Age (years)
Mean (SD) 46.6 (13.5) 46.6 (13.4) 48.6 (14.3)
n (%) n (%)
Sex
Male 191 (31.2) 166 (92.7) 13 (7.3)
Female 422 (68.8) 355 (89.6) 41 (10.4)
Education status
No formal education 11 (1.8) 8 (72.7) 3 (27.3)
Primary education 148 (24.1) 131 (93.6) 9 (6.4)
Secondary education 218 (35.6) 176 (88.9) 22 (11.1)
University education 236 (38.5) 206 (91.2) 20 (8.8)
Living with family, partner, or friend
Yes 546 (89.1) 464 (90.8) 49 (9.6)
No 67 (10.9) 57 (91.9) 5 (8.1)
Work status
Yesa 467 (76.2) 394 (89.3) 47 (10.7)
Nob 138 (22.5) 127 (94.8) 7 (5.2)
Other 8 (1.3) - -
Family history of depression
Yes 306 (49.9) 264 (90.4) 28 (9.6)
No 307 (50.1) 257 (90.8) 26 (9.2)
Is this the first episode of MDD?
Yes 270 (44.0) 237 (93.7) 16 (6.3)
No 343 (56.0) 284 (88.2) 38 (11.8)
Previous treatment for MDD
n 605 515 53
Yes 279 (46.1) 231 (88.8) 29 (11.2)
No 326 (53.9) 284 (92.2) 24 (7.8)
Missing 8 1 7
Previous treatment for current MDD episodec
n 613 521 54
Yes 589 (96.1) 501 (90.3) 54 (9.7)
No 24 (3.9) 20 (100) 0 (0.0)
Missing 0 0 0
Previous treatment duration–current MDD episodec
n 589 501 54
Mean (SD), months 5.7 (12.07) 5.9 (12.95) 5.3 (4.84)
Missing 0
RDQ (Total Score)
n 571 512 53
Table 1 Baseline characteristics for full analysis set and by
remission status at month 6 (Continued)
Mean (SD) 17.5 (14.6) 12.0 (11.1) 43.4 (16.0)
HAMD-17 (Total Score)
n 575 521 54
Mean (SD) 4.0 (2.0) 2.4 (1.9) 12.9 (4.6)
RDQ remission at baseline
n 613 517 54
Remission 461 396 (90.4) 42 (9.6)
Nonremission 148 121 (91.0) 12 (9.0)
Missing 4 4 0
RDQ remission at month 6
n 575 512 53
Remission 471 462 (98.1) 9 (1.9)
Nonremission 94 50 (53.2) 44 (46.8)
Missing 10 9 1
Abbreviations: FAS full analysis set, HAMD-17 17-item Hamilton Rating Scale for
Depression, MDD major depressive disorder, n number of patients with a non-
missing observation, RDQ remission from depression questionnaire, SD
standard deviation
aYes = part-time, self-employed, student, house-keeping, volunteer, full-time
bNo = unable to work, unemployed, retired
cCurrent episode refers to the index MDD episode that led to the patient’s
entry into the study
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−0.023, 95 % CI −0.048 to 0.003, p = 0.077), indicating
no relationship. A 1-unit higher baseline EQ-5D score
was associated with a 0.26 higher EQ-5D score at month
6 (p < 0.001, 95 % CI 0.18 to 0.34). Baseline HAMD-17
score was not a significant factor (p = 0.241) in the
analysis of EQ-5D.
Discussion
In the present study, the logistic regression models used
to assess the relationship of remission defined by several
outcome measures indicated no association between
baseline RDQ score and remission status (according to
HAMD-17) at 6 months; no association between base-
line RDQ score and composite remission status based
on the combination of QIDS-SR, SDS, and EQ-5D eval-
uations or HAMD-17 and SOFAS evaluations, health-
care resource utilization, level of quality of life
(according to EQ-5D) or relapse (according to MINI).
Additionally, there was no association between func-
tional impairment scores at baseline (according to SDS),
good functioning at baseline (according to SOFAS) and
remission status (according to HAMD-17) at 6 months.
Previous research found that remission from MDD
means more than the absence of depressive symptoms.
Zimmerman et al. [8] established that severity of depres-
sive symptoms, functional impairment, and quality of life
were significantly correlated with remission status and
that each of these variables was a significant, independ-
ent predictor of depressed patients’ subjective evalua-
tions of their remission status. Acknowledging that
symptom-based measures like the HAMD-17 do not
accommodate these additional factors, [3, 4], researchers
have advocated a broader conceptualization of remission
to assess factors beyond depressive [8, 9]. Outcome
measures like the RDQ more broadly assess the patient’s
return to normalcy and more adequately reflect the
Table 2 Treatment history for major depressive disorder
Treatment for current MDD episode
Prior to visita Baseline Month 6
N = 613 N = 613
Any treatment (n) 589 (96.1 %) NA
Psychotherapy 29 (4.9 %) NA
Tricyclic antidepressants 19 (3.2 %) NA
SSRI 303 (51.4 %) NA
SNRI 202 (34.3 %) NA
Antipsychotics 0 (0.0 %) NA
Mood stabilizers 4 (0.7 %) NA
Light therapy, ECT, or herbal remedies 0 NA
Other 32 (5.4 %) NA
At visitb Baseline Month 6
Any treatment (n) 474 (77.3 %) 377 (61.5 %)
Psychotherapy 22 (4.6 %) 14 (3.7 %)
Tricyclic antidepressants 15 (3.2 %) 15 (4.0 %)
SSRI 225 (47.5 %) 168 (44.6 %)
SNRI 182 (38.4 %) 154 (40.8 %)
Antipsychotics 2 (0.4 %) 2 (0.5 %)
Mood stabilizers 4 (0.8 %) 6 (1.6 %)
Light therapy, ECT, or herbal remedies 0 0
Other 24 (5.1 %) 18 (4.8 %)
Abbreviations: ECT, electroconvulsive therapy, MDD major depressive disorder,
N number of patients involved in the summary, n number of patients in the
given category, NA not applicable, SNRI serotonin norepinephrine reuptake
inhibitors, SSRI selective serotonin reuptake inhibitors
aApart from the row, ‘Any treatment’, all other percentages in ‘Prior to visit’
section use. n = 589 (n of patients with any treatment) as denominator
bApart from the row, ‘Any treatment’, all other percentages in ‘At visit’ section
use. n = 474 (n of patients with any treatment) as denominator
Fig. 1 Association of baseline remission from depression questionnaire with remission status by HAMD-17 at Month 6. Odds ratios and 95 %
confidence intervals are shown. The baseline HAMD-17 variable reflects a single point increase in the baseline HAMD-17 score. Abbreviations:
HAMD-17, 17-item Hamilton Rating Scale for Depression; RDQ, Remission from Depression Questionnaire
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patient’s perspective on his or her own remission status.
Clinicians’ and patients’ perceptions of remission may
disagree when patients score in the remission range on
the HAMD but do not consider themselves in remission,
[22] or conversely when patients fail to meet the HAMD
definition of remission but consider themselves in remis-
sion even though they continue to experience mild
symptom levels [22]. Additionally, several studies have
reported that a cutoff score of ≤7 may be too liberal to
consider that a patient with MDD is truly in remission
[23, 24]. The findings raise caution in relying exclusively
on symptom-based definitions of remission to guide
treatment decision-making in clinical practice. Relying
on global measures of functional impairment does little
to reduce both symptoms and impairment because
residual functional impairment may persist after symp-
toms remit [8]. A broader conceptual framework for
remission will likely capture a fuller spectrum of the
symptoms that patients use to make decisions regarding
treatment initiation and discontinuation. Measuring
both functional and symptom outcomes may help
clinicians understand and treat depression.
The fact that MDD is etiologically [25] and symptom-
atically [26] heterogeneous makes it difficult to validate
any definition of remission. The threshold used to define
remission should identify a comparatively homogeneous
group of patients with regard to current and future
morbidity, however, patients whose MDD is in remission
are heterogeneous in clinical status. Classifying them
according to cutoff scores (i.e., remitters, nonremitters)
on symptom-rating scales identifies groups who differ in
their risk of relapse and levels of current psychosocial
impairment. Patients who achieve remission have less
concurrent psychosocial impairment and lower likeli-
hood of relapse than patients who do not achieve
remission [27].
The results of the present study support observations
that functional remission is not always concurrent with
symptomatic remission [15, 28]. Once baseline symp-
toms level was taken into account, there was no associ-
ation between the odds of sustained remission with
baseline scores for functional disability based on SDS or
good functioning based on SOFAS.
In light of the lack of association between func-
tional and symptomatic remission observed in this
study, the authors turned to the RDQ subscale results
in the literature for possible explanations of the over-
all study findings. While the RDQ was found to be as
sensitive to change as the QIDS and HAMD [12] and
the effect size of the total score of the scales nearly
identical, there was variability in the effect sizes
among the RDQ subscales. The coping and function-
ing subscales had lower effect sizes than the depres-
sion symptoms subscale and changes in these
subscales were the least highly correlated with
changes in HAMD scores. These findings can be
Table 3 Logistic regression analyses
Dependent variable categorical
outcome at month 6
Independent variable
score at baseline
p-value Level/Unit Odds Ratio 95 % CI
Remission
HAMD-17 RDQ 0.439 Remission 0.76 0.38, 1.52
HAMD-17 0.009 1 unit 0.81 0.70, 0.95
Relapse
MINI RDQ 0.071 1 unit 0.98 0.96, 1.00
HAMD-17 0.007 1 unit 1.21 1.05, 1.39
Composite remission status
QIDS-SR + SDS + EQ-5D RDQ 0.553 1 unit 0.99 0.96, 1.02
HAMD-17 + SOFAS RDQ 0.374 1 unit 0.99 0.97, 1.01
Functioning
HAMD-17 SDS 0.789 No impairment 1.09 0.57, 2.09
HAMD-17 0.017 1 unit 0.81 0.69, 0.96
HAMD-17 SOFAS 0.917 Good functioning 1.03 0.55, 1.95
HAMD-17 0.024 1 unit 0.83 0.71, 0.98
Healthcare resource utilizationa
Healthcare resources RDQ 0.568 Remission 0.89 0.59, 1.33
Abbreviations: CI confidence interval, EQ-5D EuroQol, HAMD-17 17-item Hamilton Rating Scale for Depression, MINI mini-International neuropsychiatric interview,
QIDS-SR quick inventory of depressive symptomatology-self report, RDQ remission from depression questionnaire, SDS Sheehan disability scale, SOFAS social and
occupational functioning assessment scale
aHealthcare Resource Utilization was coded as a categorical outcome with at least one visit receiving a ‘Yes’
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interpreted to mean that these dimensions change
more slowly than others and as the study duration
was 6-months, the maximal benefit of treatment may
not yet have been achieved. Another possible explan-
ation is that coping and functioning are more resist-
ant to improvement than other depression symptoms;
therefore, at the end of the study, they may have
reached their maximal improvement, and the less ro-
bust changes reflect a less complete, but more accur-
ate, level of improvement [12].
Lack of association between RDQ and HAMD in our
study may reflect that a multifactorial definition may not
be more valid than a symptom-based remission defin-
ition because symptom improvement accounts for such
a large portion of the variance in determining remission
status that the assessment of the other domains does not
improve validity. Using an instrument as RDQ to
broadly evaluate domains that depressed patients con-
sider important in determining remission, we are in fact
capturing or measuring something different than what is
evaluated by the symptom-based HAMD. Lack of associ-
ation between RDQ and HAMD may be explained by
the discordance which can occur between clinicians’ and
patients’ perceptions of remission. A lack of correlation
between the QIDS, a patient-reported measure, and the
HAMD has also been observed [29].
Although, after adjustment for baseline HAMD, an
association between baseline RDQ and HAMD at
month 6 was not observed in this particular study,
the clinical use of an instrument (such as the RDQ
or a future instrument) that broadly evaluates do-
mains which may capture a more complete view of a
patient’s functioning and quality of life or improves
the prediction of which patients are likely to have a
recurrence or longer time to recurrence of depression
may be beneficial to the field. Perhaps the use of a
symptomatic endpoint (remission at 6 months) to as-
sess the impact of the value of a more complex and
broad measure that includes a patient’s point of view,
such as the RDQ, did not totally address the impact
on the prognosis of remission. In support of this,
symptom reduction or even resolution is associated
with improvement, but not necessarily with a full
normalization of function or quality of life, and re-
mission of a patient is neither rapid nor complete
even when patients meet criteria for being in symp-
tomatic remission [6].
Limitations
Certain limitations to this study must be noted. First, be-
cause an observational study design was used, patients
were not randomized to RDQ-remission status groups
and selection bias may have influenced the results. Add-
itionally, the relatively short follow-up may not reflect
the full course of the illness. More relapses may have
been observed during an extended observation period.
Lastly, the origin of the sample (i.e., patients recruited
from private medical clinics), which may explain the
relatively high educational level of the sample, consti-
tutes a relative bias. Perhaps a more heterogeneous sam-
ple might have influenced the results of the study.
Conclusion
In summary, the results of this study indicate that RDQ-
constructs are independent from remission. The RDQ is
a multidimensional measure with inherent variability on
its dimensions in terms of effect size, susceptibility to
change or improvement, etc. To determine the outcome
of treatment, clinicians should assess, in addition to
symptom resolution, factors that patients consider im-
portant in determining remission.
Table 4 Healthcare resource utilization (Baseline) by remission
from depression questionnaire baseline status
RDQ baseline status
Baseline Month 6
Remission Non-remission Remission Non-remission
N = 461 N = 148 N = 461 N = 148
Use of additional healthcare resources
n 461 148 438 133
Yes, n (%) 102 (22.1) 41 (27.7) 154 (35.2) 51 (38.3)
No, n (%) 359 (77.9) 107 (72.3) 284 (64.8) 82 (61.7)
Visits to ER or equivalent for psychiatric illness
n 102 41 154 51
Mean (SD) 0.1 (0.48) 0.1 (0.36) 0.1 (0.30) 0.1 (0.31)
Visits to ER or equivalent for nonpsychiatric illness
n 102 41 154 51
Mean (SD) 0.1 (0.46) 0.4 (0.63) 0.1 (0.52) 0.4 (0.80)
Visits to physicians other than psychiatrists
n 102 41 154 51
Mean (SD) 1.0 (1.10) 1.5 (1.25) 2.6 (3.30) 3.1 (3.94)
Psychiatric visits
n 102 41 154 51
Mean (SD) 0.8 (0.97) 1.0 (1.16) 2.2 (2.10) 2.7 (2.03)
Hospitalizations for any reason
n 102 41 154 51
Mean (SD) 0.0 (0.10) 0.0 (0.22) 0.1 (0.30) 0.1 (0.27)
Currently on sick leave due to depression
n 461 148 438 133
Yes, n (%) 5 (1.1) 7 (4.7) 3 (0.7) 4 (3.0)
No, n (%) 456 (98.9) 141 (95.3) 435 (99.3) 129 (97.0)
Abbreviations: ER emergency room, n number of patients with a non-missing
observation, RDQ remission from depression questionnaire, SD
standard deviation
Denominators for percentages are based on nonmissing data
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